Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia ; volume:34 ; number:12 ; day:21 ; month:11 ; year:2017 ; pages:2585-2600 ; date:12.2017
Advances in therapy ; 34, Heft 12 (21.11.2017), 2585-2600, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Skelly, Adrian
- Contributor
-
Carius, Hans-Joachim
Bezlyak, Vladimir
Chen, Fred K.
SpringerLink (Online service)
- DOI
-
10.1007/s12325-017-0624-6
- URN
-
urn:nbn:de:1111-2018020213359
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Skelly, Adrian
- Carius, Hans-Joachim
- Bezlyak, Vladimir
- Chen, Fred K.
- SpringerLink (Online service)
Other Objects (12)
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy